Relapse, NRM, PFS, and OS (multivariate analysis)
| . | . | . | P . | |
|---|---|---|---|---|
| Event . | n . | HR (95% CI) . | Overall . | Pairwise* . |
| NRM | ||||
| Study cohort | .36 | |||
| Haplo | 170 | 1.0 | ||
| Haplo-cord | 137 | 1.34 (0.83-2.16) | ||
| CIBMTR disease risk index | .0006 | |||
| Low | 30 | 0.9 (0.4-2.2) | .80 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.00 (1.21-3.31) | .007 | |
| Very high | 37 | 1.44 (0.94-2.18) | .09 | |
| Age, y | .01 | |||
| ≥40 | 186 | 1 | ||
| <40 | 121 | 0.51 (0.30-0.84) | ||
| Relapse/progression | ||||
| Study cohort | .6 | |||
| Haplo | 170 | 1 | ||
| Haplo-cord | 137 | 0.48 (0.31-0.75) | ||
| CIBMTR disease risk index | <.0001 | |||
| Low | 30 | 0.5 (0.2-1.4) | .19 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.35 (1.51-3.68) | .0002 | |
| Very high | 37 | 2.22 (1.66-2.97) | <.0001 | |
| Conditioning | .004 | |||
| No TBI | 253 | 1 | ||
| TBI | 54 | 0.37 (0.19-0.74) | ||
| Disease-free survival | ||||
| Study cohort | .5 | |||
| Haplo | 170 | 1 | ||
| Haplo-cord | 137 | 0.91 (0.67-1.22) | ||
| CIBMTR disease risk index | <.0001 | |||
| Low | 30 | 0.7 (0.35-1.4) | .28 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.19 (1.57-3.06) | <.0001 | |
| Very high | 30 | 1.88 (1.49-2.39) | <.0001 | |
| Conditioning | .02 | |||
| No TBI | 253 | 1 | ||
| TBI | 54 | 0.61 (0.39-0.94) | ||
| Age, y | ||||
| ≥40 | 186 | 1 | .06 | |
| <40 | 121 | 0.75 (0.55-1.02) | ||
| OS | ||||
| Study cohort | 0.21 | |||
| Haplo | 170 | 1 | ||
| Haplo-cord | 137 | 0.81 (0.62-1.18) | ||
| CIBMTR-disease risk index | <.0001 | |||
| Low | 30 | 0.8 (0.4-1.5) | .51 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.14 (1.50-3.05) | <.0001 | |
| Very high | 37 | 1.73 (1.35-2.21) | <.0001 | |
| Age, y | ||||
| ≥40 | 186 | 1 | .08 | |
| <40 | 121 | 0.74 (0.54-1.04) | ||
| . | . | . | P . | |
|---|---|---|---|---|
| Event . | n . | HR (95% CI) . | Overall . | Pairwise* . |
| NRM | ||||
| Study cohort | .36 | |||
| Haplo | 170 | 1.0 | ||
| Haplo-cord | 137 | 1.34 (0.83-2.16) | ||
| CIBMTR disease risk index | .0006 | |||
| Low | 30 | 0.9 (0.4-2.2) | .80 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.00 (1.21-3.31) | .007 | |
| Very high | 37 | 1.44 (0.94-2.18) | .09 | |
| Age, y | .01 | |||
| ≥40 | 186 | 1 | ||
| <40 | 121 | 0.51 (0.30-0.84) | ||
| Relapse/progression | ||||
| Study cohort | .6 | |||
| Haplo | 170 | 1 | ||
| Haplo-cord | 137 | 0.48 (0.31-0.75) | ||
| CIBMTR disease risk index | <.0001 | |||
| Low | 30 | 0.5 (0.2-1.4) | .19 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.35 (1.51-3.68) | .0002 | |
| Very high | 37 | 2.22 (1.66-2.97) | <.0001 | |
| Conditioning | .004 | |||
| No TBI | 253 | 1 | ||
| TBI | 54 | 0.37 (0.19-0.74) | ||
| Disease-free survival | ||||
| Study cohort | .5 | |||
| Haplo | 170 | 1 | ||
| Haplo-cord | 137 | 0.91 (0.67-1.22) | ||
| CIBMTR disease risk index | <.0001 | |||
| Low | 30 | 0.7 (0.35-1.4) | .28 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.19 (1.57-3.06) | <.0001 | |
| Very high | 30 | 1.88 (1.49-2.39) | <.0001 | |
| Conditioning | .02 | |||
| No TBI | 253 | 1 | ||
| TBI | 54 | 0.61 (0.39-0.94) | ||
| Age, y | ||||
| ≥40 | 186 | 1 | .06 | |
| <40 | 121 | 0.75 (0.55-1.02) | ||
| OS | ||||
| Study cohort | 0.21 | |||
| Haplo | 170 | 1 | ||
| Haplo-cord | 137 | 0.81 (0.62-1.18) | ||
| CIBMTR-disease risk index | <.0001 | |||
| Low | 30 | 0.8 (0.4-1.5) | .51 | |
| Intermediate | 137 | 1 | ||
| High | 110 | 2.14 (1.50-3.05) | <.0001 | |
| Very high | 37 | 1.73 (1.35-2.21) | <.0001 | |
| Age, y | ||||
| ≥40 | 186 | 1 | .08 | |
| <40 | 121 | 0.74 (0.54-1.04) | ||
Risk factors evaluated: age (<40 vs ≥40), sex, disease (AML/MDS vs lymphoma vs ALL vs other, HCT CI < 3 vs ≥3, CIBMTR DRI, use of TBI).
Reference group: intermediate.